| P50 | author | Curtiland Deville | Q39683000 |
| | Andrew R Barsky | Q86932772 |
| | Patricia Santos | Q88988857 |
| P2093 | author name string | Xingmei Wang | |
| | Justin E Bekelman | |
| | Wei-Ting Hwang | |
| | John P Christodouleas | |
| | Neha Vapiwala | |
| | Stefan Both | |
| P2860 | cites work | Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial | Q24605205 |
| | Secondary Malignancy Risk Following Proton Radiation Therapy | Q26774492 |
| | Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer | Q33761075 |
| | RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer | Q33999745 |
| | Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer | Q34268907 |
| | Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence | Q34725046 |
| | Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy | Q34794205 |
| | A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer | Q35202412 |
| | Radiation dose-volume effects in radiation-induced rectal injury | Q35870610 |
| | Fracture risk in men with prostate cancer: a population-based study. | Q35876254 |
| | Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007 | Q36163573 |
| | Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues | Q36202855 |
| | Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. | Q36407164 |
| | Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. | Q36507549 |
| | Trends in prostate cancer in the United States | Q36520517 |
| | Radiation dose-volume effects of the urinary bladder | Q36655284 |
| | Radiation dose-volume effects and the penile bulb | Q36672809 |
| | Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial | Q37128114 |
| | Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? | Q37213157 |
| | A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant | Q37389902 |
| | Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. | Q37646416 |
| | Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusing on the Incidence of Late Rectal Toxicities | Q37787414 |
| | Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer | Q37811166 |
| | Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy | Q37950717 |
| | Proton beam therapy for the treatment of prostate cancer | Q38270347 |
| | Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial | Q38402168 |
| | Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer | Q41020184 |
| | Conformal proton therapy for early-stage prostate cancer | Q41649061 |
| | Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon | Q42129004 |
| | Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer | Q42318326 |
| | Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy | Q43787924 |
| | Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. | Q45911270 |
| | Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values | Q46065408 |
| | Incidence of second malignancies among patients treated with proton versus photon radiation | Q46453281 |
| | Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. | Q47824845 |
| | Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control | Q49064521 |
| | Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. | Q50798578 |
| | Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. | Q51795552 |
| | The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. | Q51863139 |
| | Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. | Q52878001 |
| | Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience. | Q53777331 |
| | Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. | Q54766488 |
| | Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer. | Q55100642 |
| | A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiotherapy | Q56395066 |
| | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Q57280845 |
| | Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer | Q57284584 |
| | Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial | Q58603211 |
| | Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer | Q62514147 |
| | Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy | Q62616388 |
| | Patient-reported Hip Symptoms following Treatment with Proton Therapy for Prostate Cancer | Q63185736 |
| | Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) | Q63966469 |
| | Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. | Q64950302 |
| | Hip stiffness following mixed conformal neutron and photon radiotherapy: a dose-volume relationship | Q71216559 |
| | Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) | Q81057747 |
| | Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy | Q81296888 |
| | Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer | Q81371416 |
| | Bone Density Changes After Radiation for Extremity Sarcomas: Exploring the Etiology of Pathologic Fractures | Q85121298 |
| | Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients | Q88199566 |
| | Can Technological Improvements Reduce the Cost of Proton Radiation Therapy? | Q88594282 |
| | Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic | Q91085460 |
| P433 | issue | 23 | |
| P304 | page(s) | 4278-4293 | |
| P577 | publication date | 2019-09-10 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting | |
| P478 | volume | 125 | |